Shares of Intra-Cellular Therapies are surging 35% in premarket trading Monday after Johnson & Johnson said it will acquire ...

Johnson & Johnson, already a big player in neuroscience drugs, is adding to its portfolio and pipeline with a deal to acquire ...

Johnson & Johnson will spend more than $14 billion to move deeper into treating central nervous system disorders by ...

Johnson & Johnson (J&J) has agreed to pay $132 per share to acquire Intra-Cellular Therapies Inc. in a deal valued at about $14.6 billion, taking ownership of Caplyta (lumateperone), a once-daily oral ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system ...

Acquisition includes CAPLYTA® (lumateperone), the first and only U.S. FDA-approved treatment for bipolar I and II depression as an adjunctive and ...

Study from neutral host providers discovers how Wi-Fi and cellular connectivity have overtaken traditional priorities like price and amenities as top considerations for businesses choosing commercial ...

Nokia has announced that it has reached the milestone of 7,000 patent families declared as essential to 5G with more to ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Time-restricted eating, particularly among people with underlying metabolic disorders, may confer benefits beyond weight loss ...